Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1990 Oct;82(1):86–92. doi: 10.1111/j.1365-2249.1990.tb05408.x

Degradation of human myelin in vitro by leucocytes from patients with multiple sclerosis.

S J Owen 1, C M Watson 1, A N Davison 1
PMCID: PMC1535170  PMID: 2170067

Abstract

In order to study the possible autoimmune basis of multiple sclerosis (MS) a quantitative method has been used to investigate breakdown of human myelin in vitro. We found that serum from MS patients and controls was generally devoid of any myelin degradative activity. However, isolated peripheral blood mononuclear cells from 43% of MS patients showed significant myelin degradative activity as did those from 61.5% of patients with rheumatoid arthritis (RA). Myelin degradation by cells was found in only 13% of patients with other neurological diseases and in no healthy controls. It is proposed that this non-specific peripheral cellular immune degradative activity originates from cells activated within the central nervous system of MS patients or the joints of individuals with RA. As a result, activity in the blood only indirectly reflects the ongoing inflammatory response at the primary site, accounting for the lack of correlation between changes in the blood and the clinical status of the MS patient. We further propose that the lack of in vitro myelin degradative activity in cells recovered from the cerebrospinal fluid is due to autoaggressive cells being sequestered to the brain.

Full text

PDF
86

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bellamy A. S., Calder V. L., Feldmann M., Davison A. N. The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes. Clin Exp Immunol. 1985 Aug;61(2):248–256. [PMC free article] [PubMed] [Google Scholar]
  2. Bradbury K., Aparicio S. R., Sumner D. W., Bird C. C. New approach to study of in vitro toxicity of multiple sclerosis and other sera. J Neurol Sci. 1984 Aug;65(2):157–168. doi: 10.1016/0022-510x(84)90080-7. [DOI] [PubMed] [Google Scholar]
  3. Bradbury K., Aparicio S. R., Sumner D. W., Bird C. C. Role of complement in demyelination in vitro by multiple sclerosis serum and other neurological disease sera. J Neurol Sci. 1984 Sep;65(3):293–305. doi: 10.1016/0022-510x(84)90092-3. [DOI] [PubMed] [Google Scholar]
  4. Bradbury K., Aparicio S. R., Sumner D. W., Macfie A., Sagar P., Griffin N. R., Bird C. C. Comparison of in vitro demyelination and cytotoxicity of humoral factors in multiple sclerosis and other neurological diseases. J Neurol Sci. 1985 Sep;70(2):167–181. doi: 10.1016/0022-510x(85)90085-1. [DOI] [PubMed] [Google Scholar]
  5. Brosnan C. F., Selmaj K., Raine C. S. Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuroimmunol. 1988 Apr;18(1):87–94. doi: 10.1016/0165-5728(88)90137-3. [DOI] [PubMed] [Google Scholar]
  6. Brunner C., Lassmann H., Waehneldt T. V., Matthieu J. M., Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats. J Neurochem. 1989 Jan;52(1):296–304. doi: 10.1111/j.1471-4159.1989.tb10930.x. [DOI] [PubMed] [Google Scholar]
  7. Calder V., Owen S., Watson C., Feldmann M., Davison A. MS: a localized immune disease of the central nervous system. Immunol Today. 1989 Mar;10(3):99–103. doi: 10.1016/0167-5699(89)90235-1. [DOI] [PubMed] [Google Scholar]
  8. Capra R., Mattioli F., Vignolo L. A., Bettinzioli M., Cattaneo R., Franceschini F. Absence of a correlation between T lymphocyte subsets and clinical activity in relapsing-remitting multiple sclerosis. J Neuroimmunol. 1989 Mar;22(1):41–45. doi: 10.1016/0165-5728(89)90007-6. [DOI] [PubMed] [Google Scholar]
  9. Grundke-Iqbal I., Bornstein M. B. Multiple sclerosis: serum gamma globulin and demyelination in organ culture. Neurology. 1980 Jul;30(7 Pt 1):749–754. doi: 10.1212/wnl.30.7.749. [DOI] [PubMed] [Google Scholar]
  10. Hafler D. A., Weiner H. L. In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis. Ann Neurol. 1987 Jul;22(1):89–93. doi: 10.1002/ana.410220121. [DOI] [PubMed] [Google Scholar]
  11. Kurihara T., Nussbaum J. L., Mandel P. 2',3'-cyclic nucleotide 3'-phosphohydrolase in brains of mutant mice with deficient myelination. J Neurochem. 1970 Jul;17(7):993–997. doi: 10.1111/j.1471-4159.1970.tb02252.x. [DOI] [PubMed] [Google Scholar]
  12. McDonald W. I., Halliday A. M. Diagnosis and classification of multiple sclerosis. Br Med Bull. 1977 Jan;33(1):4–9. [PubMed] [Google Scholar]
  13. Moench T. R., Griffin D. E. Immunocytochemical identification and quantitation of the mononuclear cells in the cerebrospinal fluid, meninges, and brain during acute viral meningoencephalitis. J Exp Med. 1984 Jan 1;159(1):77–88. doi: 10.1084/jem.159.1.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Noronha A. B., Richman D. P., Arnason B. G. Detection of in vivo stimulated cerebrospinal-fluid lymphocytes by flow cytometry in patients with multiple sclerosis. N Engl J Med. 1980 Sep 25;303(13):713–717. doi: 10.1056/NEJM198009253031301. [DOI] [PubMed] [Google Scholar]
  15. Norton W. T., Poduslo S. E. Myelination in rat brain: method of myelin isolation. J Neurochem. 1973 Oct;21(4):749–757. doi: 10.1111/j.1471-4159.1973.tb07519.x. [DOI] [PubMed] [Google Scholar]
  16. Oehmichen M., Grüninger H., Wiethölter H., Gencic M. Lymphatic efflux of intracerebrally injected cells. Acta Neuropathol. 1979 Jan 12;45(1):61–65. doi: 10.1007/BF00691806. [DOI] [PubMed] [Google Scholar]
  17. Oger J., Kastrukoff L. F., Li D. K., Paty D. W. Multiple sclerosis: in relapsing patients, immune functions vary with disease activity as assessed by MRI. Neurology. 1988 Nov;38(11):1739–1744. doi: 10.1212/wnl.38.11.1739. [DOI] [PubMed] [Google Scholar]
  18. Ormerod I. E., Miller D. H., McDonald W. I., du Boulay E. P., Rudge P., Kendall B. E., Moseley I. F., Johnson G., Tofts P. S., Halliday A. M. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain. 1987 Dec;110(Pt 6):1579–1616. doi: 10.1093/brain/110.6.1579. [DOI] [PubMed] [Google Scholar]
  19. Owen S. J., Watson C. M., Davison A. N. Multiple sclerosis: a T-cell disease? Lancet. 1988 Oct 1;2(8614):801–801. doi: 10.1016/s0140-6736(88)92457-9. [DOI] [PubMed] [Google Scholar]
  20. Prineas J. W., Wright R. G. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest. 1978 Apr;38(4):409–421. [PubMed] [Google Scholar]
  21. Rastogi S. C., Clausen J. Membrane-bound 2',3',-cyclic nucleotide 3'-phosphohydrolase activity of lymphocytes, granulocytes and erythrocytes in multiple sclerosis. Acta Neurol Scand. 1985 Apr;71(4):303–308. doi: 10.1111/j.1600-0404.1985.tb03204.x. [DOI] [PubMed] [Google Scholar]
  22. Roth G. A., Bornstein M. B., Röyttä M., Lyman W. D., Raine C. S. Correlation between 2',3'-cyclic nucleotide 3'-phosphohydrolase activity and demyelination in vitro using a syngeneic system. J Neurochem. 1985 Feb;44(2):654–657. doi: 10.1111/j.1471-4159.1985.tb05462.x. [DOI] [PubMed] [Google Scholar]
  23. Seil F. J. Tissue culture studies of demyelinating disease: a critical review. Ann Neurol. 1977 Oct;2(4):345–355. doi: 10.1002/ana.410020417. [DOI] [PubMed] [Google Scholar]
  24. Selmaj K., Alam R., Perkin G. D., Rose F. C. T lymphocyte-derived demyelinating activity in multiple sclerosis patients in relapse. J Neurol Neurosurg Psychiatry. 1987 May;50(5):532–537. doi: 10.1136/jnnp.50.5.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Silberberg D. H., Manning M. C., Schreiber A. D. Tissue culture demyelination by normal human serum. Ann Neurol. 1984 Jun;15(6):575–580. doi: 10.1002/ana.410150610. [DOI] [PubMed] [Google Scholar]
  26. Silverman B. A., Carney D. F., Johnston C. A., Vanguri P., Shin M. L. Isolation of membrane attack complex of complement from myelin membranes treated with serum complement. J Neurochem. 1984 Apr;42(4):1024–1029. doi: 10.1111/j.1471-4159.1984.tb12706.x. [DOI] [PubMed] [Google Scholar]
  27. Sogin D. C. 2',3'-Cyclic NADP as a substrate for 2',3'-cyclic nucleotide 3'-phosphohydrolase. J Neurochem. 1976 Dec;27(6):1333–1337. doi: 10.1111/j.1471-4159.1976.tb02612.x. [DOI] [PubMed] [Google Scholar]
  28. Tournier-Lasserve E., Lyoncaen O., Roullet E., Bach M. A. IL-2 receptor and HLA class II antigens on cerebrospinal fluid cells of patients with multiple sclerosis and other neurological diseases. Clin Exp Immunol. 1987 Mar;67(3):581–586. [PMC free article] [PubMed] [Google Scholar]
  29. Ulrich J., Lardi H. Multiple sclerosis: demyelination and myelination inhibition of organotypic tissue cultures of the spinal cord by sera of patients with multiple sclerosis and other neurological diseases. J Neurol. 1978 Apr 14;218(1):7–16. doi: 10.1007/BF00314713. [DOI] [PubMed] [Google Scholar]
  30. Watson C. M., Najbauer J., Owen S. J., Davison A. N. An in vitro micromethod for the quantitative assessment of central demyelination. J Neurochem. 1988 May;50(5):1469–1477. doi: 10.1111/j.1471-4159.1988.tb03032.x. [DOI] [PubMed] [Google Scholar]
  31. Weissbarth S., Maker H. S., Lehrer G. M., Schneider S., Bornstein M. B. A sensitive fluorometric assay for 2',3'-cyclic nucleotide 3'-phosphohydrolase. J Neurochem. 1980 Aug;35(2):503–505. doi: 10.1111/j.1471-4159.1980.tb06294.x. [DOI] [PubMed] [Google Scholar]
  32. de Rosbo N. K., Bernard C. C. Multiple sclerosis brain immunoglobulins stimulate myelin basic protein degradation in human myelin: a new cause of demyelination. J Neurochem. 1989 Aug;53(2):513–518. doi: 10.1111/j.1471-4159.1989.tb07363.x. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES